Curated News
By: NewsRamp Editorial Staff
October 23, 2025
AXIM Biotech Partners with VisionPlus for Korean Dry Eye Diagnostics
TLDR
- AXIM Biotechnologies gains exclusive market access in South Korea through VisionPlus, expanding its diagnostic reach and revenue potential in a key Asian market.
- AXIM's TearScan tests use tear biomarkers analyzed by the I-Peak digital reader to differentiate dry eye types and allergies in minutes at point-of-care.
- This partnership brings precise dry eye and allergy diagnostics to Korean clinics, enabling personalized treatments that improve patient comfort and vision health.
- AXIM's tear tests can distinguish between different dry eye causes and allergies using just a small tear sample with laboratory-grade accuracy.
Impact - Why it Matters
This partnership addresses the growing global epidemic of Dry Eye Disease, which affects millions worldwide and has been exacerbated by increased screen time and environmental factors. For patients suffering from chronic eye discomfort, this collaboration means faster, more accurate diagnosis and personalized treatment options. The ability to differentiate between different types of dry eye and ocular allergies at the point of care represents a significant advancement in eye care, potentially reducing misdiagnosis and enabling more effective treatment strategies. In South Korea, where digital device usage is among the highest globally, this partnership could improve quality of life for countless individuals suffering from eye conditions that often go undiagnosed or improperly treated.
Summary
AXIM Biotechnologies, a leader in rapid point-of-care ocular diagnostics, has forged an exclusive distribution partnership with VisionPlus Corp. to bring its innovative TearScan® diagnostic platform to South Korea. Under this landmark agreement, VisionPlus receives exclusive rights to distribute AXIM's TearScan® Lactoferrin Test for detecting aqueous-deficient dry eye and TearScan® IgE Test for ocular allergy throughout the Korean market. The collaboration represents a strategic move to address the growing epidemic of Dry Eye Disease in South Korea, where VisionPlus has already established dedicated Dry Eye Clinics in anticipation of rising patient needs driven by increased digital device usage and environmental factors.
The partnership extends beyond simple distribution, with both companies committing to collaborate on Korean MFDS registration processes, targeting simultaneous submissions for both diagnostic assays. VisionPlus will leverage its established network of ophthalmology clinics, hospitals, and specialty Dry Eye Centers to drive commercialization while handling local compliance and regulatory coordination. The initial agreement spans one year with automatic one-year renewals for up to four additional years, contingent on meeting annual sales milestones. AXIM maintains manufacturing control and intellectual property ownership while providing crucial regulatory and technical support to ensure successful market entry and ongoing product quality compliance, supported by the I-Peak digital reader that delivers laboratory-grade accuracy in clinical settings.
Catalina Valencia, President of AXIM Biotechnologies, emphasized that VisionPlus represents an exceptional partner with proven commitment to advancing ocular health, citing their clinical insight and national reach as ideal for introducing AXIM's diagnostic platform. Jerry Park, President of VisionPlus Corp., highlighted how this collaboration completes their vision of creating a comprehensive diagnostic and treatment ecosystem for Dry Eye Disease and related conditions. The TearScan® platform's ability to provide quantitative tear biomarker analysis in minutes using minimal tear samples represents a significant advancement in ocular diagnostics, enabling clinicians to differentiate between aqueous-deficient dry eye, evaporative dry eye, and allergic conjunctivitis—critical distinctions that directly impact treatment selection and patient monitoring outcomes.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, AXIM Biotech Partners with VisionPlus for Korean Dry Eye Diagnostics
